Relief Therapeutics Holding SA

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
N/A
SEDOL
BR103W0
CIK
N/A
relieftherapeutics.com
LEI: 506700IT19260EVD7916
©
New: Infographics X-Lab
FIGI: BBG000C4N8Q6
RLF
Relief Therapeutics Holding SA
GICS: - · Sektor: - · Sub-Sektor: -
AI
PROFILER
NAME
Relief Therapeutics Holding SA
ISIN
CH1251125998
TICKER
RLF
MIC
XSWX
REUTERS
RLFB.S
BLOOMBERG
RLF SW
F&G: 63
12.008,00 SMI · 15,83 Vola-Index · 117.819,61 BTC · 0,94114 EURCHF
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von ACCESS Newswire bereitgestellt.
Do., 14.08.2025       Relief Therapeutics
CH1251125998

GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year report and provided a co...
Read More
Relief Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Mo., 11.08.2025       Relief Therapeutics
CH1251125998

GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has advanced the publication date of its 2025 ...
Read More
Relief Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Di., 29.07.2025       Relief Therapeutics
CH1251125998

NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disordersBusiness combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech companyBinding term sheet signed; transaction subject to customary...
Read More
Relief Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Fr., 20.06.2025       Relief Therapeutics
CH1251125998

GENEVA, SWITZERLAND / ACCESS Newswire / June 20, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its initial request for Qualified Infectious Disease...
Read More
Relief Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Do., 12.06.2025       Relief Therapeutics
CH1251125998

Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESS Newswire / June 12, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, toda...
Read More
Relief Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Do., 22.05.2025       Relief Therapeutics
CH1251125998

GENEVA, SWITZERLAND / ACCESS Newswire / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has grant...
Read More
Relief Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Do., 15.05.2025       Relief Therapeutics
CH1251125998

GENEVA, SWITZERLAND / ACCESS Newswire / May 15, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published the agenda for its 2025 Annual General Meeting (AGM) of shareholders, to ...
Read More
Relief Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Do., 10.04.2025       Relief Therapeutics
CH1251125998

GENEVA, SWITZERLAND / ACCESS Newswire / April 10, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its 2024 Annual Report and provided a corporate update. In his annual l...
Read More
Relief Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Do., 06.03.2025       Relief Therapeutics
CH1251125998

GENEVA, SWITZERLAND / ACCESS Newswire / March 6, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that discussions regarding a potential merger with Renexxion, I...
Read More
Relief Therapeutics
Technical Analysis Termsheet Terminal
Permalink
Di., 11.02.2025       Relief Therapeutics
CH1251125998

Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rar...
Read More
Relief Therapeutics
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

BARRISTA SMART * AD

P R O D U C T   S U G G E S T I O N S